PRX00933 (5HT2c agonist for obesity)

Obesity represents an area of huge unmet medical need. New products may be available in the next few years, for example Qnexa and Contrave, both combinations of on-market products. However, given the size of the potential market (market opportunity is forecast to be $12.2bn by 2018, Datamonitor), there is an opportunity to develop novel therapies for use as a monotherapy and also in combination with existing anti-obesity agents. Sales for anti-obesity drugs across the seven major markets were only $514 million in 2008, a small number given the potential market size, mainly due to the limitations of existing treatments.

PRX00933 (formerly BVT933) belongs to a new class of drug candidates that effect weight loss through selective activation of 5HT2c receptors located in the brain. PRX00933 demonstrated significant weight loss in a Phase II clinical trial and is the next most advanced 5HT2c agonist following Lorcaserin, which was submitted for FDA approval in December 2009. PRX00933 was shown to be safe and well tolerated in over 450 patients in previous clinical development programmes. The compound is now entering further development, including non-clinical combination studies for obesity and diabetes.

PRX00933 Highlights

  • PRX00933 is a 5HT2c agonist
  • PII data showing significant weight loss
  • Safe and well tolerated in over 450 patients
  • Non-clinical studies in progress

Contact us

For more information about any of the Proximagen programmes please contact our Head of Business Development, Tim Sparey

+44(0)20 7848 8215

+44(0)20 7848 6034


Back to Science Pipeline chart